BB BIOTECH AG: Disclosure of Shareholdings

EQS Voting Rights Announcement: BB BIOTECH AG
BB BIOTECH AG: Disclosure of Shareholdings

10.05.2024 / 17:40 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Disclosure of Shareholdings

Published, 08/05/2024

Notification ID: 95e58c52-be79-4dff-913a-3d312fe9da73

Notification of Collective Investment Schemes

PART 1: LICENSEE

Company name and head office of the licensee resp. for foreign collective
investment schemes, which are not authorized for sale and are not dependent
from a group of companies, company name and head office of the fund
administration or the investment company:

Company: UBS Fund Management (Switzerland) A

City: Basel

Country: Switzerland

PART 2: COLLECTIVE INVESTMENT SCHEME/S

Name of collective investment scheme/s which hold/s individually 3% or more
voting rights

PART 3: DATE AND REASON FOR THE REPORTING OBLIGATION

Date of the act that creates the obligation to notify: 30.04.2024

Date of transfer of equity securities (if different from date of the act
which
creates the obligation to notify):

Facts and circumstances triggering the obligation to notify (art. 22 para. 1
b FMIO-FINMA):

Acquisition

Sale

Creation of a group

Change in group composition Termination of a group

Discretionary exercise of voting rights

Securities lending and comparable transactions

Exercise, non-exercise or expiration of derivative holdings

Granting (writing) of derivative holdings

Capital increase

Capital reduction

Ipso jure transfer or transfer due to a decision by a court or public
authority

Change in the information subject to the obligation to notify

Other X
Disclosure triggered due to the absorption merger ("Absorptionsfusion")
between Credit Suisse Funds AG and UBS Fund Management (Switzerland) AG and
the aggregation of the relevant interest of both entities as upon merger
Credit Suisse Funds AG ceased to exist and UBS Fund Management (Switzerland)
AG was the surviving entity.


Total of voting rights below 3%

If the participation falls below the threshold of 3% (purchase positions and
sale positions), no indication in Part 4 or Part 5 is required.

Total of voting rights <3%

PART 4: PURCHASE POSITIONS PURSUANT TO ART. 14 PARA. 1 A FMIO-FINMA

Total of all purchase positions:

Total of all equity securities or equity related securities (item 1), number
of voting rights that can be exercised at one's own discretion (item 3) and
derivative holdings (item 4)

        Number of voting rights                    Percentage
     S1 = (1.1) + (3.1) + (4.1)    S2 = (1.2) + (3.2) + (4.2)
                      2,413,177                        4.356%

Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting
rights pursuant to the entry in the commercial register (see Central
Business Names Index) or Publication according to art. 115 para. 3 FMIO:

55,400,000

1. Equity securities or equity related securities

              Shares     Number  Voting rights1
                                         Number  Percentage2
    Registered share  2,413,177       2,413,177       4.356%
               Total                      (1.1)        (1.2)
                                      2,413,177       4.356%
  1. Whether exercisable or not

  2. Calculated on the basis of the total number of voting rights pursuant
    to the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

2. Securities lending and comparable transactions in equity securities

Of the equity securities mentioned in item 1 above, the following part is
held due to securities lending and comparable transactions (art. 17
FMIO-FINMA):

  S-  N-  Proport-     Nature  Agreed date of return transfer or, if there is
  h-  u-  ion of       of the  a right to choose, whether this applies to the
  a-  m-  voting        legal  contracting party subject to the obligation to
  r-  b-  rights    transact-                   notify or to the counterparty
  e-  e-                  ion
   s   r
  3. Voting rights that can be exercised at one's own discretion

The following voting rights were delegated by a third party and can be
exercised at one's own discretion.

Voting rights

Is the person who has full discretionary powers to exercise voting rights
directly or indirectly controlled?

Yes No

4. Derivative holdings

Conversion and share purchase rights (such as call-options according to art.
15 para. 2 a FMIO-FINMA), granted (written) share sale rights and other
derivative holdings:

  Type    Number  Number of             Security ID number (ISIN) if
  of      of      voting rights         available or basic terms
  right-  rights  conferred
  s
                  Number         Perc-  Identity of issuer, subscription
                                 enta-   ratio, exercise price, exercise
                                 ge2               period, exercise type

(4.1) (4.2)

Total

2 Calculated on the basis of the total number of voting rights pursuant to
the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)

5. Securities lending and comparable transactions in derivative holdings

Of the derivative holdings mentioned in item 4 above, the following part is
held due to securities lending and comparable transactions (art. 17
FMIO-FINMA):

  Nature    Num-    Number  Propor-     Agreed date of return transfer or, if
  of the    ber         of  tion     there is a right to choose, whether this
  legal     of    reporte-  of       applies to the contracting party subject
  transac-  rig-         d  voting      to the obligation to notify or to the
  tion      hts     voting  rights                               counterparty
                    rights

PART 5: SALE POSITIONS PURSUANT TO ART. 14 PARA. 1 B FMIO-FINMA

Total of all sale positions:
Basis of calculation (art. 14 para. 2 FMIO-FINMA): total number of voting
rights pursuant to the entry in the commercial register (see Central
Business Names Index) or Publication according to art. 115 para. 3 FMIO:

55,400,000

Derivative holdings

Share sale rights (such as put-options according to art. 15 para. 2 a
FMIO-FINMA), granted (written) conversion and share purchase rights and
other derivative holdings:

  Type    Number  Number of             Security ID number (ISIN) if
  of      of      voting rights         available or basic terms
  right-  rights  conferred
  s
                  Number         Perc-  Identity of issuer, subscription
                                 enta-   ratio, exercise price, exercise
                                 ge2               period, exercise type

Total

2 Calculated on the basis of the total number of voting rights pursuant to
the entry in the commercial register (art. 14 para. 2 FMIO-FINMA)


---------------------------------------------------------------------------

10.05.2024 CET/CEST The EQS Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:    English
   Company:     BB BIOTECH AG
                Schwertstrasse 6
                8200 Schaffhausen
                Switzerland
   Internet:    www.bbbiotech.ch

End of News EQS News Service
---------------------------------------------------------------------------

1900663 10.05.2024 CET/CEST